AXGN trades 41.2% below Wall Street's consensus target of $52.80.
Last 12 months price action with 12-month analyst target path
The base valuation assumes AXGN achieves its forward estimates and maintains a stable P/E multiple of 83.7x. This scenario reflects the blended consensus of 20 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of October 3, 2026, AxoGen, Inc. (AXGN) has a Wall Street consensus price target of $52.80, based on estimates from 20 covering analysts. With the stock currently trading at $37.39, this represents a potential upside of +41.2%. The company has a market capitalization of $2.01B.
Analyst price targets range from a low of $50.00 to a high of $55.00, representing a 9% spread in expectations. The median target of $53.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 17 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, AXGN trades at a trailing P/E of -110.0x and forward P/E of 83.7x. Analysts expect EPS to grow +171.0% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 TELATELA Bio, Inc. | $51M | $1.14 | — | — | — | — | — |
 NVCRNovocure Ltd | $1.7B | $14.94 | $26.00 | +74.0% | Buy | — | 15 |
 XTNTXtant Medical Holdings, Inc. | $49M | $0.35 | — | — | — | — | — |
 MDXGMiMedx Group, Inc. | $669M | $4.59 | $7.67 | +67.1% | Buy | — | 15 |
 ANIKAnika Therapeutics, Inc. | $256M | $19.10 | $21.00 | +9.9% | Buy | 18.2x | 7 |
 RGENRepligen Corporation | $10.3B | $181.70 | $162.43 | -10.6% | Buy | 88.2x | 24 |
 ISRGIntuitive Surgical, Inc. | $138.5B | $391.95 | $491.15 | +25.3% | Buy | 36.3x | 57 |
 SYKStryker Corporation | $105.6B | $275.43 | $370.16 | +34.4% | Buy | 18.4x | 52 |
 ZBHZimmer Biomet Holdings, Inc. | $17.1B | $88.29 | $103.11 | +16.8% | Hold | 10.3x | 42 |
 HOLXHologic, Inc. | $17.0B | $76.01 | $78.69 | +3.5% | Hold | 17.2x | 42 |
Quick answers to the most common questions about buying AXGN stock.
The consensus Wall Street price target for AXGN is $52.8, representing 41.2% upside from the current price of $37.39. With 20 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
AXGN has a consensus rating of "Buy" based on 20 Wall Street analysts. The rating breakdown is predominantly bullish, with 17 Buy/Strong Buy ratings. The consensus 12-month price target of $52.8 implies 41.2% upside from current levels.
At a forward P/E of 83.684x, AXGN trades at a premium valuation. The consensus price target of $52.8 (41.2% upside) suggests analysts still see growth justifying the multiple.
The most bullish Wall Street analyst has a price target of $55 for AXGN, while the most conservative target is $50. The consensus of $52.8 represents the median expectation. These targets typically reflect 12-month expectations.
AXGN is well covered by analysts, with 20 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 17 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month AXGN stock forecast based on 20 Wall Street analysts shows a consensus price target of $52.8, with estimates ranging from $50 (bear case) to $55 (bull case). The median consensus rating is "Buy".
AXGN trades at a forward P/E ratio of 83.7x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on AXGN, with a "Buy" consensus rating and $52.8 price target (41.2% upside). 17 of 20 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
AXGN analyst price targets range from $50 to $55, a 9% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $52.8 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.